JP2016525544A - 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 - Google Patents

抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 Download PDF

Info

Publication number
JP2016525544A
JP2016525544A JP2016529754A JP2016529754A JP2016525544A JP 2016525544 A JP2016525544 A JP 2016525544A JP 2016529754 A JP2016529754 A JP 2016529754A JP 2016529754 A JP2016529754 A JP 2016529754A JP 2016525544 A JP2016525544 A JP 2016525544A
Authority
JP
Japan
Prior art keywords
injection
pharmaceutical composition
triamcinolone
composition according
moxifloxacin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016529754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525544A5 (enExample
Inventor
ジェフリー・ティ・リーグナー
ジョン・スコット・キャロルチク
バーナード・コバルスキー
リチャード・ディルザー
キャラン・ピータース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harrow Inc
Original Assignee
Imprimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50640013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2016525544(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imprimis Pharmaceuticals Inc filed Critical Imprimis Pharmaceuticals Inc
Publication of JP2016525544A publication Critical patent/JP2016525544A/ja
Publication of JP2016525544A5 publication Critical patent/JP2016525544A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2016529754A 2013-07-22 2014-03-27 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 Pending JP2016525544A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361958170P 2013-07-22 2013-07-22
US61/958,170 2013-07-22
PCT/US2014/032026 WO2015012899A1 (en) 2013-07-22 2014-03-27 Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019108368A Division JP7232128B2 (ja) 2013-07-22 2019-06-11 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物

Publications (2)

Publication Number Publication Date
JP2016525544A true JP2016525544A (ja) 2016-08-25
JP2016525544A5 JP2016525544A5 (enExample) 2017-04-06

Family

ID=50640013

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016529754A Pending JP2016525544A (ja) 2013-07-22 2014-03-27 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
JP2019108368A Active JP7232128B2 (ja) 2013-07-22 2019-06-11 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
JP2021083925A Pending JP2021121608A (ja) 2013-07-22 2021-05-18 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
JP2022157885A Active JP7362870B2 (ja) 2013-07-22 2022-09-30 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
JP2023172708A Pending JP2024001149A (ja) 2013-07-22 2023-10-04 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019108368A Active JP7232128B2 (ja) 2013-07-22 2019-06-11 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
JP2021083925A Pending JP2021121608A (ja) 2013-07-22 2021-05-18 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
JP2022157885A Active JP7362870B2 (ja) 2013-07-22 2022-09-30 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
JP2023172708A Pending JP2024001149A (ja) 2013-07-22 2023-10-04 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物

Country Status (10)

Country Link
US (1) US20150024996A1 (enExample)
EP (1) EP3024475B8 (enExample)
JP (5) JP2016525544A (enExample)
KR (1) KR20160033213A (enExample)
AU (1) AU2014293665B2 (enExample)
BR (1) BR112016001544A8 (enExample)
CA (1) CA2919081C (enExample)
IL (1) IL243750A0 (enExample)
MX (1) MX383077B (enExample)
WO (1) WO2015012899A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
KR20160033213A (ko) * 2013-07-22 2016-03-25 임프리미스 파마슈티컬스 인코포레이티드 항균제 및 항염증제를 포함하는 안구내 투여를 위한 약학적 조성물
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
JP6682898B2 (ja) * 2016-02-17 2020-04-15 富士通株式会社 基地局、無線通信システムおよび基地局の処理方法
KR20190109604A (ko) * 2016-05-06 2019-09-25 해로우 헬스 인코포레이티드 약학적 안과용 조성물 및 그의 제조 방법
DK3541442T3 (da) 2016-11-16 2022-03-14 Persica Pharmaceuticals Ltd Antibiotiske formuleringer mod lændesmerter
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
US12102632B2 (en) 2020-08-26 2024-10-01 Somerset Therapeutics, Llc Quinolone dispersions
US11484538B2 (en) 2020-08-26 2022-11-01 Somerset Therapeutics, Llc Bromfenac, prednisolone, and moxifloxacin compositions and methods
US11523987B2 (en) 2020-08-26 2022-12-13 Somerset Therapeutics, Llc Trimcinolone and moxifloxacin methods
US11382910B2 (en) 2020-08-26 2022-07-12 Somerset Therapeutics, Llc. Loteprednol and moxifloxacin compositions and methods
EP4260844A1 (en) 2022-04-11 2023-10-18 Liegner, Jeffery T. Ophthalmological compositions comprising poloxamer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1192368A (ja) * 1997-07-23 1999-04-06 Ono Pharmaceut Co Ltd ベンゾピラン誘導体を主成分とする水性液剤
JP2002522373A (ja) * 1998-08-03 2002-07-23 インサイト・ビジョン・インコーポレイテッド 眼への投与方法
JP2003176228A (ja) * 2001-12-11 2003-06-24 Rohto Pharmaceut Co Ltd 液 剤
JP2008540532A (ja) * 2005-05-10 2008-11-20 アルコン，インコーポレイテッド 活性成分、ポロキサマー界面活性剤もしくはメロキサポール界面活性剤およびグリコールを含有する懸濁処方物、ならびに眼の障害を処置するための医薬の製造のためのその使用
JP2013508381A (ja) * 2009-10-21 2013-03-07 オトノミ―，インク． ポロクサマーを包含する製剤のゲル化温度の調節

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049552A1 (en) * 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
US20080262415A1 (en) * 2005-07-18 2008-10-23 Peyman Gholam A Enhanced wound healing
EP2962682B1 (en) * 2008-12-11 2018-03-28 Massachusetts Institute Of Technology Method of making a contact lens drug delivery device
WO2011049958A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
US20140127269A1 (en) * 2012-02-13 2014-05-08 The Schepens Eye Research Institute, Inc. Anti-Inflammatory Peptide Derived From Thrombospondin-1 and Uses Thereof
KR20160033213A (ko) * 2013-07-22 2016-03-25 임프리미스 파마슈티컬스 인코포레이티드 항균제 및 항염증제를 포함하는 안구내 투여를 위한 약학적 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1192368A (ja) * 1997-07-23 1999-04-06 Ono Pharmaceut Co Ltd ベンゾピラン誘導体を主成分とする水性液剤
JP2002522373A (ja) * 1998-08-03 2002-07-23 インサイト・ビジョン・インコーポレイテッド 眼への投与方法
JP2003176228A (ja) * 2001-12-11 2003-06-24 Rohto Pharmaceut Co Ltd 液 剤
JP2008540532A (ja) * 2005-05-10 2008-11-20 アルコン，インコーポレイテッド 活性成分、ポロキサマー界面活性剤もしくはメロキサポール界面活性剤およびグリコールを含有する懸濁処方物、ならびに眼の障害を処置するための医薬の製造のためのその使用
JP2013508381A (ja) * 2009-10-21 2013-03-07 オトノミ―，インク． ポロクサマーを包含する製剤のゲル化温度の調節

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANGELUCCI,D.: "Best Paper Of Session Intracameral injection studied to replace post-op eyedrops", [ONLINE], JPN5016008337, January 2006 (2006-01-01), ISSN: 0003974391 *
ERMIS,S.S. ET AL: "Treatment of Staphylococcus Epidermidis Endophthalmitis with Intravitreal Moxifloxacin in a Rabbit M", TOHOKU J. EXP. MED., vol. 205, JPN6017039290, 2005, pages 223 - 229, ISSN: 0003974389 *
KUMAR,B.V. ET AL: "Trans-zonular delivery of intravitreal triamcinolone acetonide in the management of pre-existing mac", ACTA OPHTHALMOLOGICA SCANDINAVICA, vol. 84, no. 3, JPN6017039298, 2005, pages 438 - 439, ISSN: 0003841290 *
LIPNER,M.: "Perioperative pharmacology Bucking the drop trend", [ONLINE], JPN6017039288, May 2012 (2012-05-01), ISSN: 0003974387 *
PAGANELLI,F. ET AL: "A Single Intraoperative Sub-Tenon's Capsule Injection of Triamcinolone and Ciprofloxacin in a Contro", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 50, no. 7, JPN6017039292, 2009, pages 3041 - 3047, ISSN: 0003974390 *
PATHENGAY,A. ET AL: "Intravitreal Triamcinolone Acetonide in the Management of Exogenous Bacterial Endophthalmitis", AMERIAN JOURNAL OF OPHTHALMOLOGY, vol. 141, no. 5, JPN6017039296, 2006, pages 938 - 940, ISSN: 0003841289 *
SAKALAR,Y.B. ET AL: "Treatment of Experimental Bacillus cereus Endophthalmitis Using Intravitreal Moxifloxacin With or Wi", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol. 27, no. 6, JPN5016008340, 2011, pages 593 - 598, ISSN: 0003974388 *
WISKUR,B.J. ET AL: "Toward Improving Therapeutic Regimens for Bacillus Endophthalmitis", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 49, no. 4, JPN6017039295, 2008, pages 1480 - 1487, ISSN: 0003974392 *
プロメテウス解剖学アトラス頭頸部／神経解剖, vol. 第２版, JPN6019004046, 1 January 2014 (2014-01-01), pages 143 - 158, ISSN: 0003974393 *

Also Published As

Publication number Publication date
EP3024475A1 (en) 2016-06-01
JP2021121608A (ja) 2021-08-26
AU2014293665A1 (en) 2016-02-11
NZ716208A (en) 2020-12-18
HK1223824A1 (zh) 2017-08-11
JP2022185059A (ja) 2022-12-13
IL243750A0 (en) 2016-04-21
JP2019167376A (ja) 2019-10-03
MX2016000964A (es) 2016-08-03
MX383077B (es) 2025-03-13
JP7362870B2 (ja) 2023-10-17
CA2919081C (en) 2021-11-16
BR112016001544A2 (pt) 2017-07-25
CA2919081A1 (en) 2015-01-29
EP3024475B1 (en) 2020-09-30
WO2015012899A1 (en) 2015-01-29
AU2014293665B2 (en) 2017-06-01
JP2024001149A (ja) 2024-01-09
BR112016001544A8 (pt) 2021-08-03
KR20160033213A (ko) 2016-03-25
EP3024475B8 (en) 2020-11-18
JP7232128B2 (ja) 2023-03-02
US20150024996A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
JP7362870B2 (ja) 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
US11684570B2 (en) Pharmaceutical ophthalmic compositions
US11510916B2 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160184323A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20150129457A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160101118A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160243031A1 (en) Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US20160175323A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
JP6694525B2 (ja) 薬学的眼病用組成物およびそれを製造するための方法
US20190105320A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20190111045A1 (en) Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US9814673B2 (en) Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof
US20160045432A1 (en) Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof
WO2016024956A1 (en) Intraocular lens comprising fluoroquinolone and a corticosteroid and methods for fabricating thereof
KR20230145894A (ko) 폴록사머를 포함하는 안과적 조성물
HK40105104A (en) Ophthalmological compositions comprising poloxamer
CN119326771A (zh) 包含泊洛沙姆的眼科组合物
HK1223824B (en) Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent
WO2020117497A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181019

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190212